Table 1.
Patient characteristics. Summary measures presented are N (%) when categorical and median (min, max) when continuous.
| Variable | Summary measure |
|---|---|
| Age at diagnosis | 65 years (39.1, 82.9) |
| Sex | |
| Male | 105 (68.2) |
| Female | 49 (31.8) |
| Race | |
| White | 135 (87.7) |
| Black | 6 (3.9) |
| Asian | 2 (1.3) |
| Other/unknown | 11 (7.1) |
| Smoking status | |
| Never | 30 (19.5) |
| Former | 83 (53.9) |
| Current | 41 (26.6) |
| cT stage | |
| cT2 | 69 (44.8) |
| cT3 | 74 (48.1) |
| cT4a | 11 (7.1) |
| Histology | |
| UC | 105 (68.2) |
| UC, mixed | 49 (31.8) |
| Palpable mass on EUA | |
| Yes | 37 (24.0) |
| No | 63 (40.9) |
| N/A | 54 (35.1) |
| Mobile bladder on EUA | |
| Yes | 95 (61.7) |
| No | 5 (3.2) |
| N/A | 54 (35.1) |
| Hydronephrosis | |
| Yes | 41 (26.6) |
| No | 113 (73.4) |
| KPS | |
| 70 | 2 (1.3) |
| 80 | 36 (23.4) |
| 90 | 116 (75.3) |
| Chemotherapy regimen | |
| Split-dose | 112 (72.7) |
| Standard | 40 (26.0) |
| Gemcitabine weekly | 2 (1.3) |
| Chemotherapy treatment time (days) | 86.0 (21.0, 121.0) |
| Days | |
| Days from chemotherapy end to RC-PLND * | 33.5 (0.0, 106.0) |
| Cycles completed | 4.0 (0.5, 4.0) |
| Gemcitabine dose intensity | 615.4 mg/m2/week (289.3, 746.7) |
| Cisplatin dose intensity | 21.5 mg/m2/week (10.1, 26.1) |
| Gemcitabine total dose | 8000 mg/m2 (1000, 12000) |
| Cisplatin total dose | 280.0 mg/m2 (25.0, 295.0) |
| pT stage: patients (%) | |
| pT0 | 32 (21) |
| pTa | 2 (1) |
| pTis | 25 (16) |
| pT1 | 12 (8) |
| pT2 | 22 (14) |
| pT3 | 55 (36) |
| pT4 | 6 (4) |
| pTa + pTcis + pT1 | 39 (25) |
| pT0 + pTa + pTcis + pT1 (<pT2) | 71 (46) |
| ≥pT2 | 83 (54) |
| Median total lymph nodes | 19.0 (0.0, 61.0) |
| Positive lymph nodes | |
| Yes | 32 (21) |
| No | 122 (79) |
| Median Number positive Lymph Nodes (32) | 3.0 (1.0, 12.0) |
| Positive margin (bladder or urethra) | |
| Yes | 11 (7.1) |
| No | 143 (92.9) |
*
Imputed end date of chemotherapy was used. In one patient, chemotherapy was terminated mid-cycle and RC was performed 3 weeks after the last dose, with a 0-day interval between the imputed cycle end date and the date of RC.